Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




miRNAs Show Promise for Treatment of Ovarian Cancer

By LabMedica International staff writers
Posted on 21 Aug 2012
Results of a recent study suggest that microRNAs (miRNAs) have excellent therapeutic potential, which justifies continued research efforts designed to turn them into usable anticancer agents.

Investigators at the Georgia Institute of Technology (Atlanta, GA, USA) worked with two well-defined mRNA species, MiR-7 and MiR-128. More...
They conducted a series of controlled experiments in which these two miRNAs--previously implicated in ovarian cancer onset/progression--were individually transfected into a well-defined ovarian cancer (HEY) cell line, and the consequence on global patterns of gene expression was monitored using microarray technology.

The results published in the August 1, 2012, online edition of the journal BMC Medical Genomics revealed that the changes in gene expression induced by the individual miRNAs were functionally coordinated but distinct between the two miRNAs. MiR-7 transfection into ovarian cancer cells induced changes in cell adhesion and other developmental networks previously associated with epithelial-mesenchymal transitions (EMT) and other processes linked with metastasis. In contrast, miR-128 transfection induced changes in cell cycle control and other processes commonly linked with cellular replication.

“Each inserted miRNA created hundreds of thousands of gene expression changes, but only about 20% of them were caused by direct interactions with mRNAs,” said senior author Dr. John McDonald, professor of biology at the Georgia Institute of Technology. “The majority of the changes were indirect – they occurred downstream and were consequences of the initial reactions. miRNAs have evolved for millions of years in order to coordinately regulate hundreds to thousands of genes together on the cellular level. If we can understand which miRNAs affect which suites of genes and their coordinated functions, it could allow clinicians to attack cancer cells on a systems level, rather than going after genes individually”.

Related Links:
Georgia Institute of Technology




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.